Form 13-F position report

VTV THERAPEUTICS INC

Reported by MORGAN STANLEY

VTVT CUSIP 918385204 Manager CIK 0000895421

Reported 17,476 shares, up 16,467 (1632.0%) from the prior quarter.

Reported value 1318.7%; share count 1632.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 17,476 Quarter-end amount reported
Reported value $538,960 Fair value at quarter end
Consecutive quarters held 41 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 206000
2022-03-31 25000
2022-06-30 25000
2022-09-30 32000
2022-12-31 22165
2023-03-31 27014
2023-06-30 24740
2023-09-30 15985
2023-12-31 0
2023-12-31 9660
2024-03-31 19765
2024-06-30 14834
2024-09-30 11395
2024-12-31 15824
2025-03-31 12921
2025-06-30 11190
2025-09-30 17419
2025-12-31 39071
2026-03-31 45807
2026-06-30 37989
2026-09-30 538960

Quarterly position history

How this manager's reported quarter-end position changed over time.

21 quarters
Quarterly reported position history for VTV THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 17,476 +16,467 (1632.0%) < 0.01% $538,960 2026-11-13
Q2 2026 Reduced 1,009 -146 (-12.6%) < 0.01% $37,989 2026-08-13
Q1 2026 Added 1,155 +178 (18.2%) < 0.01% $45,807 2026-05-15
Q4 2025 Added 977 +231 (31.0%) < 0.01% $39,071 2026-02-13
Q3 2025 Unchanged 746 0 (0.0%) < 0.01% $17,419 2025-11-14
Q2 2025 Unchanged 746 0 (0.0%) < 0.01% $11,190 2025-08-15
Q1 2025 Reduced 746 -400 (-34.9%) < 0.01% $12,921 2025-05-15
Q4 2024 Added 1,146 +306 (36.4%) < 0.01% $15,824 2025-02-14
Q3 2024 Unchanged 840 0 (0.0%) < 0.01% $11,395 2024-11-14
Q2 2024 Unchanged 840 0 (0.0%) < 0.01% $14,834 2024-08-14
Q1 2024 Unchanged 840 0 (0.0%) < 0.01% $19,765 2024-05-15
Q4 2023 New 840 +840 (0.0%) < 0.01% $9,660 2024-02-13
Q4 2023 Reduced 0 -33,442 (-100.0%) 0 $0 2024-02-13
Q3 2023 Unchanged 33,442 0 (0.0%) < 0.01% $15,985 2023-11-15
Q2 2023 Unchanged 33,442 0 (0.0%) < 0.01% $24,740 2023-08-14
Q1 2023 Unchanged 33,442 0 (0.0%) < 0.01% $27,014 2023-05-15
Q4 2022 Reduced 33,442 -1 (0.0%) < 0.01% $22,165 2023-02-14
Q3 2022 Unchanged 33,443 0 (0.0%) < 0.01% $32,000 2022-11-14
Q2 2022 Reduced 33,443 -1,723 (-4.9%) < 0.01% $25,000 2022-08-15
Q1 2022 Reduced 35,166 -172,087 (-83.0%) < 0.01% $25,000 2022-05-13
Q4 2021 Added 207,253 +128,358 (162.7%) < 0.01% $206,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

50 managers reported VTV THERAPEUTICS INC for Q3 2026.

Managers reporting VTV THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Samsara BioCapital LLC Added 354,730 +56,234 1.04% $10,939,873 12 qtrs
MILLENNIUM MANAGEMENT LLC Added 342,481 +72,607 < 0.01% $10,562,114 6 qtrs
FMR LLC Unchanged 260,391 0 < 0.01% $8,030,458 11 qtrs
Siren L L C Unchanged 163,000 0 0.12% $5,026,920 5 qtrs
BAKER BROS ADVISORS LP Unchanged 148,314 0 0.02% $4,574,004 11 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 81,740 -12,723 < 0.01% $2,520,862 3 qtrs
Trails Edge Capital Partners LP Reduced 76,989 -8,203 0.34% $2,374,341 4 qtrs
Aisling Capital Management LP Added 58,775 +8,775 0.61% $1,812,621 2 qtrs
TWO SIGMA INVESTMENTS LP Added 47,654 +36,168 < 0.01% $1,469,649 2 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 24,350 -8,120 < 0.01% $751,697 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
CL A NEW

Voting authority reported

Sole
16,730
Shared
0
None
746

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.